Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success ...
Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. ACU-D1 is under development for the treatment of severe acne rosacea ...
Here at NBC Select, a lot happened in 2024. We celebrated our second-annual Wellness Awards, where we tested hundreds of products in categories like fitness tech, workout apparel and sleep.
As menopause is a natural part of aging and there is no cure for rosacea, treatments aim to reduce the symptoms. Managing the emotional and physical effects of rosacea and menopause can be ...